Warning letter
Taro Pharmaceuticals, Inc [ARCHIVED]: warning letter of Feb 5, 2009
FDA warning letter 42738 · Center for Drug Evaluation and Research
Key facts
| Reference number | 42738 |
|---|---|
| Company | Taro Pharmaceuticals, Inc [ARCHIVED] |
| Subject | CGMP for Deviations/Adulterated |
| Issue date | Feb 5, 2009 |
| Posted date | Feb 5, 2009 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 211.192, 211.166(a), 314.81(b)(1)(ii), 211.137(a), 211.22(a), 211.22 |
| Inspection city | Brampton |
| Inspection start date | Jul 28, 2008 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- VAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: